
Finding the necessary capital to continue operations has been smooth sailing for biotech company Synklino, which reported on Monday that a financing round has concluded, bringing in DKK 106m (USD 16.2m).
Synklino had only expected a third of that figure, but the investment round was popular among old and new investors alike. This included the existing backers, Nordic funds Vækstfonden and Eir Ventures, as well as current management and board members, in addition to 70 new investors, comprising both private investors and interested family offices, and new institutional investors such as Strategic Investments.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app